全文获取类型
收费全文 | 75894篇 |
免费 | 6376篇 |
国内免费 | 21篇 |
出版年
2021年 | 653篇 |
2020年 | 567篇 |
2019年 | 719篇 |
2018年 | 919篇 |
2017年 | 870篇 |
2016年 | 1442篇 |
2015年 | 2391篇 |
2014年 | 2731篇 |
2013年 | 3748篇 |
2012年 | 4593篇 |
2011年 | 4751篇 |
2010年 | 3126篇 |
2009年 | 2826篇 |
2008年 | 4189篇 |
2007年 | 4308篇 |
2006年 | 4119篇 |
2005年 | 4085篇 |
2004年 | 4184篇 |
2003年 | 3770篇 |
2002年 | 3778篇 |
2001年 | 862篇 |
2000年 | 599篇 |
1999年 | 828篇 |
1998年 | 1099篇 |
1997年 | 760篇 |
1996年 | 701篇 |
1995年 | 752篇 |
1994年 | 737篇 |
1993年 | 685篇 |
1992年 | 621篇 |
1991年 | 596篇 |
1990年 | 578篇 |
1989年 | 614篇 |
1988年 | 526篇 |
1987年 | 508篇 |
1986年 | 456篇 |
1985年 | 591篇 |
1984年 | 741篇 |
1983年 | 636篇 |
1982年 | 759篇 |
1981年 | 794篇 |
1980年 | 720篇 |
1979年 | 498篇 |
1978年 | 555篇 |
1977年 | 526篇 |
1976年 | 525篇 |
1975年 | 402篇 |
1974年 | 495篇 |
1973年 | 450篇 |
1970年 | 282篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
Hemant Kulkarni Peter J. Meikle Manju Mamtani Jacquelyn M. Weir Marcio Almeida Vincent Diego Juan Manuel Peralta Christopher K. Barlow Claire Bellis Thomas D. Dyer Laura Almasy Michael C. Mahaney Anthony G. Comuzzie Harald H. H. G?ring Joanne E. Curran John Blangero 《Journal of lipid research》2014,55(5):939-946
Plasma lipidome is now increasingly recognized as a potentially important marker of chronic diseases, but the exact extent of its contribution to the interindividual phenotypic variability in family studies is unknown. Here, we used the rich data from the ongoing San Antonio Family Heart Study (SAFHS) and developed a novel statistical approach to quantify the independent and additive value of the plasma lipidome in explaining metabolic syndrome (MS) variability in Mexican American families recruited in the SAFHS. Our analytical approach included two preprocessing steps: principal components analysis of the high-resolution plasma lipidomics data and construction of a subject-subject lipidomic similarity matrix. We then used the Sequential Oligogenic Linkage Analysis Routines software to model the complex family relationships, lipidomic similarities, and other important covariates in a variance components framework. Our results suggested that even after accounting for the shared genetic influences, indicators of lipemic status (total serum cholesterol, TGs, and HDL cholesterol), and obesity, the plasma lipidome independently explained 22% of variability in the homeostatic model of assessment-insulin resistance trait and 16% to 22% variability in glucose, insulin, and waist circumference. Our results demonstrate that plasma lipidomic studies can additively contribute to an understanding of the interindividual variability in MS. 相似文献
4.
Sinisa Bjelic Yakov Kipnis Ling Wang Zbigniew Pianowski Sergey Vorobiev Min Su Jayaraman Seetharaman Rong Xiao Gregory Kornhaber John F. Hunt Liang Tong Donald Hilvert David Baker 《Journal of molecular biology》2014
Designed retroaldolases have utilized a nucleophilic lysine to promote carbon–carbon bond cleavage of β-hydroxy-ketones via a covalent Schiff base intermediate. Previous computational designs have incorporated a water molecule to facilitate formation and breakdown of the carbinolamine intermediate to give the Schiff base and to function as a general acid/base. Here we investigate an alternative active-site design in which the catalytic water molecule was replaced by the side chain of a glutamic acid. Five out of seven designs expressed solubly and exhibited catalytic efficiencies similar to previously designed retroaldolases for the conversion of 4-hydroxy-4-(6-methoxy-2-naphthyl)-2-butanone to 6-methoxy-2-naphthaldehyde and acetone. After one round of site-directed saturation mutagenesis, improved variants of the two best designs, RA114 and RA117, exhibited among the highest kcat (> 10− 3 s− 1) and kcat/KM (11–25 M− 1 s− 1) values observed for retroaldolase designs prior to comprehensive directed evolution. In both cases, the > 105-fold rate accelerations that were achieved are within 1–3 orders of magnitude of the rate enhancements reported for the best catalysts for related reactions, including catalytic antibodies (kcat/kuncat = 106 to 108) and an extensively evolved computational design (kcat/kuncat > 107). The catalytic sites, revealed by X-ray structures of optimized versions of the two active designs, are in close agreement with the design models except for the catalytic lysine in RA114. We further improved the variants by computational remodeling of the loops and yeast display selection for reactivity of the catalytic lysine with a diketone probe, obtaining an additional order of magnitude enhancement in activity with both approaches. 相似文献
5.
Felix Schiele John Park Norbert Redemann Gerd Luippold Herbert Nar 《Journal of molecular biology》2014
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is associated with autosomal dominant hypercholesterolemia, a state of elevated levels of LDL (low-density lipoprotein) cholesterol. Autosomal dominant hypercholesterolemia can result in severe implications such as stroke and coronary heart disease. The inhibition of PCSK9 function by therapeutic antibodies that block interaction of PCSK9 with the epidermal growth factor-like repeat A domain of LDL receptor (LDLR) was shown to successfully lower LDL cholesterol levels in clinical studies. Here we present data on the identification, structural and biophysical characterization and in vitro and in vivo pharmacology of a PCSK9 antibody (mAb1). The X-ray structure shows that mAb1 binds the module 1 of the C-terminal domain (CTD) of PCSK9. It blocks access to an area bearing several naturally occurring gain-of-function and loss-of-function mutations. Although the antibody does not inhibit binding of PCSK9 to epidermal growth factor-like repeat A, it partially reverses PCSK9-induced reduction of the LDLR and LDL cholesterol uptake in a cellular assay. mAb1 is also effective in lowering serum levels of LDL cholesterol in cynomolgus monkeys in vivo. Complete loss of PCSK9 is associated with insufficient liver regeneration and increased risk of hepatitis C infections. Blocking of the CTD is sufficient to partially inhibit PCSK9 function. Antibodies binding the CTD of PCSK9 may thus be advantageous in patients that do not tolerate complete inhibition of PCSK9. 相似文献
6.
7.
8.
9.
10.